Introduction
Imatinib mesylate (IM), also known as Gleevec, Glivec or STI571, is a tyrosine kinase inhibitor that was approved by the Food and Drug Administration (FDA) in 1999. After only a few years, IM became a revolutionary molecule in the treatment of chronic myeloid leukemia (CML). Because it is a selective inhibitor of the break point cluster region-c-Abelson fusion gene (BCR-ABL), IM has become the most effective treatment for CML over the last decade. After five years of treatment of CML patients who had not previously reached accelerated (AP) or blast crisis phases (BC) and who were in the early chronic phase (CP) [i.e., they started IM treatment within 12 months of diagnosis and had not received any other treatments, such as interferon-alpha (IFN-α) or an allogeneic stem cell transplant], the rates of complete cytogenetic response (CCR) (that is 0% Philadelphia chromosome -Ph) and progression-free survival were 87% and 90%, respectively (1) . Although these results are encouraging, 10% to 15% of treated patients still show resistance to IM treatment (1, 2) . The known mechanisms of resistance are mutations in the kinase domain of the ABL gene. IM binds to this region of the ABL gene to prevent phosphorylation of BCR-ABL1, thereby inhibiting its action as an activator of proliferation regulatory, differentiation regulatory and apoptosis inhibitory genes (3) . Other less common resistance mechanisms (described in patients who have failed treatment) include BCR-ABL1 gene amplification, expression of the multidrug resistance (MDR1) gene and its encoded P-glycoprotein (that expel IM from the inside of the CML cells) (2) and the absence of hOCT1 expression (4) or OCT1 protein activity, the action of which favors the entry of IM into CML leukemic cells (5) . IM has a bioavailability of approximately 98% when ingested orally, and because its halflife is 20 hours, it can be administered once daily (6) . Although the pharmacokinetic properties of IM are favorable, several cases of suboptimal responses have been described according to the European Leukemia Net (7, 8) , and even treatment failure due to variations in the plasma threshold of IM has been reported (9, 10) . IM is metabolized via the cytochrome P450 system; specifically, the isoenzyme CYP3A4 is responsible for almost all IM metabolism. CGP74588, which is the primary IM metabolite, has the same biological properties and represents 20% of IM plasma levels in patients treated with this drug (6) .
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Evaluating IM in the serum of CML patients has become an important parameter for achieving therapeutic levels of IM in patients susceptible to interactions with other drugs or only to adjust drug dosage (11) . Numerous published studies have validated the use of chromatographic techniques to quantify IM and its metabolite (CGP74588) in human plasma (12) (13) (14) . The most widely used technique for detecting this drug and its metabolite in patient serum is liquid chromatography coupled with mass spectrometry or ultraviolet spectrophotometry detection (15) . The goal of the present study is to report a method that was developed and has been fully validated to quantify imatinib and its metabolite (CGP74588) in human serum. This method has several advantages over previously published methods, particularly the decreased time required for sample processing and analysis, the increased simplicity of the extraction method and the reduced use of biological material, solvents and other materials and equipment (11, 12, (16) (17) (18) (19) . The validated method can be used as an auxiliary tool for monitoring patient compliance to imatinib mesylate treatment because it is able to detect and quantify therapeutic levels of this drug.
Methods
The method proposed to quantify imatinib in human serum is based on a protein precipitation extraction technique associated with an instrumental analysis using ultrafast liquid chromatography coupled with mass spectrometry (UFLC-MS), which has been fully validated.
Method validation
The method validation employs carefully planned experiments to verify that the method achieves the prerequisites for the proposed application. The parameters evaluated included selectivity, precision, accuracy, recovery and linearity. The procedures and evaluation criteria adopted comply with Resolution RE 899 of the 2003 "Guide for bioanalytical method validation" of the Brazilian Health Surveillance Agency (Agência Nacional de Vigilância Sanitária -ANVISA) and the "Guidance for Industry: Bioanalytical Method Validation" of the FDA, USA (20, 21) .
Materials:
The biological material selected to develop and validate this method was human serum. Common materials found in analytical laboratories were used, such as type-1 deionized water, high performance liquid chromatography (HPLC) grade methanol, formic acid and pharmaceutical-grade ammonium acetate, 2-mL polypropylene centrifuge tubes, automatic pipettes, disposable plastic pipette tips and borosilicate glass vials with plastic caps (for the automatic injector). The equipment used included the following: an R5424 Eppendorf centrifuge, a Shimadzu UFLC-MS liquid chromatograph consisting of a Prominence binary pump system, automatic injector and column oven, and a LCMS2020 spectrometer (Shimadzu, Japan). The analytical standards for IM, its metabolite CGP74588 and internal standards for imatinib-D8 were provided by Novartis (Brazil SA). To validate and prepare the calibration curves and quality controls, human serum samples that were free of the drug were obtained from voluntary donations at the São Paulo Blood Center, São Paulo, Brazil. A total of six matrices from different individuals were used, including four normal, one hyperlipidemic and one hemolyzed sample.
Instrument conditions:
Chromatographic separation was performed on a Phenomenex Luna C18 column (50 x 2 mm; 3 μm) using a water and methanol gradient for the mobile phase; both the methanol and water were supplemented with the modifiers ammonium acetate (10 mM) and formic acid (0.1%). The run started with 20% methanol for 2 minutes with a linear gradient from 20% to 100% being later applied over seven minutes; 100% was kept until the tenth minute, returning to the initial condition (20% methanol) to re-equilibrate the column for 3 minutes. The mass spectrometer employed an atmospheric pressure ionization interface in positive ESI (electrospray) mode. The detection parameters comprised the coincidence of retention times (5.8 min) with ions monitored in a single ion monitoring (SIM) mode with m/z ratios of 494, 480 and 502 for imatinib, the metabolite CGP74588 and the deuterated internal standard Imatinib-D8, respectively.
Procedures

Preparation of solutions:
The primary solution, working solution, calibration curve and quality controls were prepared. All solutions were properly identified and stored at 8°C in polypropylene tubes. The primary solutions of imatinib, its metabolites and the internal standard were prepared in 1 mL of 100% methanol (HPLC grade) to obtain concentrations of 0.50 mg/mL, 0.50 mg/mL and 0.25 mg/mL, respectively. From these primary solutions, working solutions were prepared as mixtures of imatinib and its metabolite (CGP74588) at a final concentration of 200 μg/mL; these mixtures were the precursor solutions for preparing the calibration curves and the quality controls. The calibration curve consisted of a blank (biological matrix not containing the drug standard and internal standard), a zero sample (biological matrix processed with the internal standard) and eight samples containing the drug standard and internal standard. All unknown samples were stored at -20°C prior to quantification.
Preparation of samples:
The established and validated extraction procedure consisted of 100-mL aliquots of serum samples [corresponding to the blank, zero, calibration controls, quality controls (QCA, QCB, QCC) and unknown samples] in 2.0-mL polypropylene tubes. Subsequently, 50 mL of the internal standard solution (Imatinib-D8 solution, 5.0 mg/mL) and 400 mL of chilled methanol were added to the respective samples and stirred for 20 s. The tubes were centrifuged for 15 minutes at 16,000 x g, and the supernatants were transferred to glass vials and stored in the automatic injector until analysis. In total 2 mL of each sample was injected into the chromatographic system.
Analysis of samples
The method was applied to different doses of imatinib in serum samples from 308 patients whose BCR-ABL gene measurements had been quantified (to monitor disease progression based on treatment consisting of 400 mg/day imatinib). Data were evaluated without identifying the patients (i.e., samples were assigned a defined conditions. To validate this method, intra-run and interrun precision tests (intermediate precision) were performed. The precision was expressed as a relative standard deviation (RSD) or coefficient of variation (CV%), not including values greater than 15% (except for the LLOQ, for which values less than or equal to 20% were included) (20) . The imatinib results obtained were as follows: 2.0% RSD for intra-assay tests and 5.5% RSD for inter-assay tests. The results for the metabolite (CGP74588) were as follows: 1.6% RSD for intra-assay tests and 6.2% for inter-assay tests.
Accuracy:
The accuracy of a method provides a measure of the proximity between the experimental results and the magnitude of the nominal values being evaluated, which should be determined in the same analytical run (intra-run precision), as well as between runs (inter-run precision). Deviations should not exceed 15%, except for the limit of quantification, for which deviations less than or equal to 20% are permissible (20) . The imatinib results obtained were as follows: 102.2% accuracy for intra-assay tests and 101.1% accuracy for inter-assay tests. The metabolite (CGP74588) results obtained were as follows: 108.9% accuracy for intra-assay tests and 104.8% accuracy for inter-assay tests.
Recovery:
The efficiency of an extraction procedure for a bioanalytical and analytical method within a limit of variation is measured by the recovery. A percent recovery near 100% for the analyte and the internal standard is desirable; however, lower values are acceptable since the recovery is precise and accurate (20) . To validate the method, the recovery was evaluated using different types (normal, hemolyzed and lipemic) of human serum at three concentration levels (QCA, QCB and QCC). For this method, the recovery obtained for the different types of human serum and over the intended concentration range was approximately 100%.
Linearity: Three calibration curves were prepared, analyzed independently and evaluated. Each concentration was calculated by correlating the nominal concentration with the ratio between the area of the analyte and the area of the internal standard (response). The calibration curves had determination coefficients greater than 0.98, and the deviations of each calibration solution in relation to its nominal value did not exceed 20% for the LLOQ or 15% for all other concentrations, clearly reaching the ANVISA Resolution RE 899 standards of 2003. Except for the calibration solutions at the extremes, which were prepared in duplicate, calibration curves were prepared using single calibration solutions.
Limits of detection and quantification:
The LOD was determined as the concentration capable of producing a response in the instrumental analysis with a signal/noise ratio greater than 3; the LOD was 0.100 mg/mL in these experiments. The lower limit of quantification was 0.500 mg/mL, which was validated for accuracy and precision as described herein and had a signal/noise ratio greater than 10 compared to blank matrix samples.
Stability:
Based on these validated procedures, the standards and imatinib samples in serum showed no significant degradation within the limits adopted by the laboratory for the temperature, humidity, time and materials used. corresponding sample numbers). The following conditions applied to the statistical analyses: (i) only the results of patients with these two results (imatinib serum levels and BCR-ABL quantification) were included, and (ii) the patients with imatinib concentrations < 0.100 mg/mL (limit of detection -LOD) were excluded. A total of 308 samples were included in the study. This set of 308 samples was further divided into two subgroups: one with 223 samples that achieved better treatment response (MMR) (i.e., a BCR-ABL/BCR ratio ≤ 0.1% according to an international scale) (22) and another with the remaining 85 samples (non-MMR). Statistical analyses were based on calculations of mean, median and first and third quartile values. The first quartile (Q1) is the value below which 25% of the observations fall, and the third quartile (Q3) is the value below which 75% of the observations fall. Thus, the Q1-Q3 interval corresponds to 50% of the observations. The results were compared to recently published reports.
Calculations and statistical analyses
Data were recorded in Microsoft Excel ® 2010 spreadsheets for statistical analyses. Calculations were performed using the program's preset functions and graphs were generated using the "Histogram" data analysis tool. The concentration calculations and correlation of the calibration curves in the instrumental analysis (HPLC-MS) were performed using LC-Solutions ® equipment software (Shimadzu, Japan).
Results
Method validation was fully completed, including the parameters, procedures and limits recommended by the bioanalytical guidelines (20, 21) . The parameters that were evaluated included selectivity, precision, accuracy, recovery at three concentration levels (QCA 1.50 mg/mL, QCB 4.50 mg/mL and QCC 8.10 mg/mL) and linearity with standard samples at concentrations of 0.500, 1.00, 2.00, 4.00, 6.00, 8.00 and 10.0 mg/mL. Selectivity: Selectivity defines the ability of the method to identify a compound in the presence of other components (such as impurities, degradation products and matrix components) (20, 23) . To validate this method, the occurrence of carry-over in the chromatographic system, cross-talk in the spectrometer and interferences in response to the sample matrix used as a blank were determined. To evaluate carry-over, the standard with the highest concentration was injected followed by a blank solvent sample. For cross-talk testing, analytes and the internal standard were individually injected. To determine whether there was interference in the blank sample, the extraction procedure was performed on a sample containing no analytes or internal standards, and the resulting solution was analyzed using the chromatographic conditions proposed in the method; these results were compared with the results obtained using an analyte sample at a concentration near the lower limit of quantification (LLOQ) that was determined in the solvent. No significant effects were observed (greater than 20% of LLOQ) that would affect the accuracy of quantification. Therapeutic monitoring: In the 308 samples analyzed, the imatinib serum levels were between 0.138 mg/mL and 2.816 mg/mL. The median and mean were 1.319 mg/mL and 1.403 mg/mL, respectively. In the subset whose samples achieved MMR (223 samples), imatinib serum concentrations were between 0.144 mg/mL and 2.816 mg/mL, and the median and mean were 1.344 mg/mL and 1.404 mg/mL, respectively. In the subset where MMR was not observed (non-MMR, n = 85), imatinib serum concentrations were between 0.138 mg/mL and 3.011 mg/mL and the median and mean were 1.274 mg/mL and 1.401 mg/mL, respectively. Figure 1 shows a histogram of the distribution of imatinib concentrations in the MMR samples. The ranges defined by quartiles and frequencies are indicated on the histogram. Figure 2 shows the results of three sets of data in a box-plot, as well as the parameters used to calculate these data.
Discussion
Imatinib mesylate is still the drug of choice for treating CML (24) . Several studies have suggested that treatment with decreasing doses of imatinib mesylate, ranging from 800 mg/day to 400 mg/day, would yield a better treatment response for CML in the chronic phase of the disease. These results were obtained by monitoring blood levels of imatinib and comparing these levels to response indicators, such as the hematological response (HR), cytogenetic response (CR) and the molecular response (MR) to BCR-ABL/gene control (25) . Dose-reduction studies, such as the Phase 3 clinical studies designated TOPS (acronym for Tyrosine Kinase Inhibitor Optimization and Selectivity), which compared 400 mg/day doses to 800 mg/day doses, have reported reductions in adverse side effects. The TOPS studies showed that both the MMR and the CCR occurred more quickly in patients who received 800 mg/day doses, although the responses achieved by both dosages were equivalent at the end of one year (25) . Thus, it is worth assessing the relationship between imatinib dosage (and its levels in the blood) and the efficacy of treatment (measured by CCR and MMR) as a means of titrating the dose to reduce adverse side effects while maintaining the benefits of treatment. One recently published study showed that at steady state, the minimum imatinib levels are relatively stable over time and proportional to the dose administered. The study also showed that patients with concentrations above 1.165 mg/mL after the first month of treatment achieved MMR and CCR more quickly after one year of follow-up (26) .
Doses of imatinib
Figure 1 shows significant differences in the distribution of values between the following three data sets: (i) all of the data, (ii) only patients who achieved MMR, and (iii) patients for which MMR was not achieved (non-MMR). These results indicate that in a given population, maintaining higher serum concentrations is directly related to achieving MMR, while low serum concentrations correlate with a failure to achieve MMR. In fact, the highest mean (and median) concentrations occurred in the MMR subgroup. These results are notably similar to results previously reported for other populations (9, 10, 26) . There is a significant difference in the distribution of values between sets, especially in relation to the median and amplitude of the values. The horizontal line at the concentration of 1344 μg/mL corresponds to the median of better treatment response set, which is significantly higher than the non-MMR group. Values are in μg/mL It is noteworthy that the serum concentrations measured in the present study were higher than those previously reported for plasma. This result indicates that the serum matrix used in this study contains relatively higher concentrations of imatinib (10, 16, 26) . Population differences that have not been taken into account may also affect this comparison.
The results herein demonstrate the importance of implementing validated analytical methods to monitor imatinib levels in the blood to better individualize treatment, particularly for individuals who have adverse or exacerbated side effects or that present with abnormal MMR and CCR (26, 27) . Although previous studies have employed liquid chromatography to quantify imatinib and its metabolite (CGP74588), the objective of the present study was to develop and fully validate a method that quantifies imatinib and its metabolite in human serum using UFLC-MS with a single quadrupole mass detector adapted for routine laboratory application. This validated method has several advantages over previously published methods, including decreased consumption of materials, solvents and reagents, greater speed of analysis and increased simplicity of sample preparation. These advantages render the method robust enough to quantify approximately one hundred samples per day with decreased generation of chemical or biological waste.
Conclusions
The method developed in this study is specific, selective, robust, precise and accurate for quantitatively analyzing imatinib and its metabolite CGP74588 with a low limit of quantification (0.500 mg/mL) and a low limit of detection (0.100 mg/mL) in serum. These concentration detection levels are suitable for detecting therapeutic doses of the medication. This method has been fully validated for several parameters, including selectivity, precision, accuracy, linearity, recovery, limits of detection and limits of quantification, and the technique meets the criteria established by the FDA and ANVISA validation guidelines.
Based on these results and their agreement with previously published reports, it is essential for research centers to implement validated analytical methods to monitor imatinib levels in the blood during CML treatment to better individualize therapy while minimizing adverse side effects and maximizing the therapeutic effects of the treatment.
The Laboratory of Tumor Biology of the Hematology Service at HC-FMUSP has successfully implemented routine analyses of imatinib in serum as a means of diagnostic support during treatment, demonstrating that it is an important tool in monitoring treatment compliance.
